The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity

NCT06830343 · Recruiting

Last updated 2026-05-28

This clinical trial tests the safety and effects of the drug SYH9017 in Chinese adults who are overweight or have obesity.

Status Recruiting Currently enrolling participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 66 people Planned (estimated).

Who can join Ages 18–60 · all sexes

Timeline Started 2025-02 · est. completion 2026-10

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06830343 ↗

Description as written by the study sponsor.

This is a randomized, double-blind, single-center, dose-escalation, single ascending dose and multiple ascending dose study of SYH9017 in Chinese participants with overweight and obesity.

Treatments tested

SYH9017 Drug

subcutaneous injection once time in SAD and four times in MAD
Placebo Drug

subcutaneous injection once time in SAD and four times in MAD
Wegovy ® Drug

subcutaneous injection once a week

Main thing measured	Incidence of AEs following single-dose administration of SYH9017 Description:
Sponsor	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Conditions studied	Overweight or Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06830343 ↗